Filtern
Volltext vorhanden
- ja (68)
Gehört zur Bibliographie
- ja (68)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (68)
Schlagworte
- multiple myeloma (5)
- gene expression (4)
- Hodgkin lymphoma (3)
- Medizin (3)
- apoptosis (3)
- Activation (2)
- CD30 (2)
- CXCR4 (2)
- T cells (2)
- T-cell lymphoma (2)
- amplicon sequencing (2)
- anaplastic large cell lymphoma (2)
- cancer (2)
- cell staining (2)
- cell-cycle arrest (2)
- flow cytometry (2)
- gene regulation (2)
- lymphoma (2)
- machine learning (2)
- metastasis (2)
- survival (2)
- thymus (2)
- 3D lung tumor tissue models (1)
- AKT-signaling (1)
- ALCL (1)
- ALK-1 (1)
- ATG7 (1)
- Antibodies (1)
- B cell malignancies (1)
- B cells (1)
- B-MYB (1)
- B-cell lymphoma (1)
- BIRC7 (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Bone marrow cells (1)
- Bone marrow transplantation (1)
- Breast-cancer (1)
- Bruton Tyrosine Kinase (1)
- B‐cell lymphoma (1)
- CD/metabolism (1)
- CD274 (1)
- CD319 (1)
- CD40 ligand (1)
- CRC (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- CX5461 (1)
- CXCR4/SDF-1 (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer treatment (1)
- Chains (1)
- Clonality (1)
- Cushings syndrome (1)
- DHAP (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- Defined burkitts lymphoma (1)
- Delta Repertoire (1)
- Design (1)
- EBER in situ hybridization (1)
- EBV (1)
- EMT (1)
- EZH1 (1)
- EZH2 (1)
- Epitope (1)
- Epstein-Barr virus (1)
- Expression (1)
- FDG PET/CT (1)
- FFPE (1)
- Fak regulation (1)
- Frequency (1)
- GIST (1)
- Gene-expression (1)
- Genome wide analysis (1)
- GvHD (1)
- H3K27me3 (1)
- HD (1)
- Hans algorithm (1)
- High-resolution (1)
- Histone deacetylase inhibition (1)
- IL-17 (1)
- IRF4 (1)
- Ibrutinib (1)
- Induced apoptosis (1)
- Intestinal Intraepithelial Lymphocy (1)
- KIT (1)
- KRAS (1)
- KRAS biomarker signatures (1)
- Kidney cancer (1)
- LESA (1)
- Ligand (1)
- Lipom (1)
- Lung-cancer (1)
- LyP (1)
- Lymph2Cx assay (1)
- Lymphoma (1)
- Lymphomas (1)
- MEK/ERK-signaling (1)
- MIZ1 (1)
- MTB (1)
- MTCH2 (1)
- MTX (1)
- MYC (1)
- Malignancies (1)
- Mantle cell lymphoma (1)
- Mechanisms (1)
- Medical research (1)
- Microarray (1)
- Migration (1)
- Molecular pathogenesis (1)
- Multiple (1)
- Myb-MuvB (1)
- Myeloma cells (1)
- Myelomas (1)
- NF-Kappa-B (1)
- NFAT (1)
- NFATc1 (1)
- NGS (1)
- NLPHL (1)
- Nuclear expression (1)
- Organoids (1)
- PCI-32765 (1)
- PET (1)
- PLAG1 rearrangement (1)
- PTCL (1)
- Pathogenesis (1)
- Pathway (1)
- Phase- (1)
- Positron emission tomography (1)
- Profiling (1)
- Prognosis (1)
- Proliferation (1)
- Promoter (1)
- R-CHOP (1)
- RCC (1)
- RNA probe (1)
- RNAPOL1 (1)
- Renal cell carcinoma (1)
- Rituximab plus (1)
- Riutximab (1)
- SGN-35 (1)
- Sox9 (1)
- Spleen (1)
- Sprue (1)
- Stromal cells (1)
- Survival (1)
- T cell receptors (1)
- T(H)17 cells (1)
- T-cell non-Hodgkin's lymphomas (1)
- T-cell transfer (1)
- T-follicular regulatory cell (1)
- TCR (1)
- TCR signaling cascade (1)
- Targeted Therapies (1)
- Targets (1)
- Th17 (1)
- Transcription-factor (1)
- Translational research (1)
- Tregs (1)
- Tumor Microenvironment (1)
- Tumour markers (1)
- USP9X (1)
- Usage (1)
- XIAP (1)
- YAP (1)
- [\(^{68}\)Ga] pentixafor (1)
- abnormalities (1)
- actin (1)
- acute graft-versus host disease (1)
- acute myeloid leukaemia (1)
- adenomas (1)
- adrenal tumor (1)
- adrenocortical cancer (1)
- alloreactive T cells (1)
- alternative splicing (1)
- aluminum granuloma (1)
- amplifications (1)
- anaplastic large cell lymphoma (ALCL) (1)
- anaplastic medulloblastoma (1)
- animal model (1)
- anti-CD30 drug conjugate (1)
- antigen loss (1)
- antigens (1)
- antioxidant function (1)
- aortic adventitia (1)
- autoimmune disease (1)
- autologous transplantation (1)
- autophagy (1)
- biosynthesis (1)
- bone disease (1)
- bone marrow cells (1)
- boolean in silico models (1)
- brain tumor (1)
- breast cancer (1)
- c-myc (1)
- cancer care (1)
- cancer detection (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer stem cells (1)
- cancers and neoplasms (1)
- carcinogenesis (1)
- carcinoma (1)
- carcinomas (1)
- case report (1)
- caspase-3 (1)
- catenin (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell death (1)
- cell of origin (1)
- cells (1)
- chemokine receptor (1)
- children (1)
- chromosomes (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- combined therapy (1)
- comparative genomic hybridization (1)
- complement system (1)
- consensus DNA (1)
- cutaneous T-cell-lymphoma (1)
- cyclophsophamide (1)
- cytotoxicity (1)
- damage (1)
- damage responses (1)
- deletions (1)
- diagnostics (1)
- diffuse large B-cell lymphoma (1)
- disease (1)
- distinct (1)
- drug resistance (1)
- ectopic lymphoid follicle (1)
- enhancer (1)
- enzyme-linked immunoassays (1)
- ephitelial cells (1)
- epigenetics (1)
- epithelium (1)
- expression (1)
- extramedullary disease (1)
- features (1)
- fluorescence in situ hybridisation (1)
- follicular lymphoma (1)
- forecasting (1)
- gRNA-only (1)
- gastrointestinal infections (1)
- gene (1)
- genetic loci (1)
- genomic aberrations (1)
- germline mutation (1)
- glioblastoma (1)
- grade 3B (1)
- group 3 (1)
- growth patterns (1)
- helper T cells (1)
- hemophagocytosis (1)
- high numbers (1)
- high-dose chemotherapy (1)
- high-resolution analysis (1)
- human genome (1)
- imaging (1)
- immune checkpoint blockade (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- immunotherapeutics (1)
- in vivo imaging (1)
- in-vitro (1)
- in-vivo (1)
- independent predictor (1)
- inflammation-induced tissue demage (1)
- invasion (1)
- involvement (1)
- kidney cancer (1)
- kidneys (1)
- kinase (1)
- large cell transformation (1)
- latency type (1)
- lesions (1)
- lineage (1)
- lipoblastoma (1)
- livin (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphohistiocytosis (1)
- lymphoid aggregate (1)
- lymphoid hyperplasia (1)
- lymphomatoid papulosis (1)
- mTOR (1)
- major histocompatibility complex (1)
- malignancies (1)
- malignant tumors (1)
- mantel cell lymphoma (1)
- mantle cell lymphoma (1)
- marcophages (1)
- marrow transplantation (1)
- mast cells (1)
- mastocytosis (1)
- measles virus (1)
- meningeal inflammation (1)
- mesenteric lymph node (1)
- mesentery (1)
- metabolism (1)
- methylation (1)
- miR-126 (1)
- miR-21 (1)
- miRNA (1)
- mice (1)
- microenvironment (1)
- mitochondrial DNA (1)
- mitosis (1)
- mitotic genes (1)
- molecular subtypes (1)
- monoclonal antibody (1)
- mouse models (1)
- mtDNA (1)
- mutant p53 (1)
- mutation (1)
- myasthenia (1)
- myasthenia gravis (1)
- mycosis fungoides (1)
- naive T-cell gene editing (1)
- network (1)
- neutral loss (1)
- next generation sequencing (1)
- nodular lymphcyte (1)
- notch signaling (1)
- obinutuzumab (1)
- organoids (1)
- orthotopic xenograft (1)
- outcomes research (1)
- outreach (1)
- p53 (1)
- p53-dependent apoptosis (1)
- p53-inducible regulator (1)
- pan-RCC (1)
- pancreatic cancer (1)
- panel sequencing (1)
- panel-sequencing (1)
- panniculitis (1)
- pathology (1)
- pathway (1)
- patient access (1)
- pediatric (1)
- pediatric lymphoma (1)
- peripheral T-cell (1)
- plasma cells (1)
- pleural mesothelioma (1)
- poor prognosis (1)
- positron emission tomography (1)
- precision oncology (1)
- primary cutaneous follicular B-cell lymphoma (1)
- prognostic factor (1)
- progressive multiple sclerosis (1)
- pseudolymphoma (1)
- psoas muscle (1)
- rare SNP (1)
- real world data (1)
- receptor tyrosine kinases (1)
- refractory/relapsed lymphoma (1)
- regression analysis (1)
- regulatory T-cells (1)
- relapse (1)
- renal cancer (1)
- renal cell carcinoma (1)
- restoration (1)
- retroperitoneal tumor (1)
- reverse transcriptase-polymerase chain reaction (1)
- ribosome (1)
- seminoma (1)
- senescence (1)
- serum (1)
- slice culture (1)
- stemness (1)
- suppression (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical oncology (1)
- systemic and cutaneous CD30+ lymphoproliferations (1)
- systemic sclerosis (1)
- target validation (1)
- targeted (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- targeted therapies (1)
- theranostics (1)
- thymic carcinoma (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymoma (1)
- transcription (1)
- transcriptional repression (1)
- transformation (1)
- translocation (1)
- tumor heterogeneity (1)
- tumor microenvironment (1)
- tumor spheroids (1)
- tumor-vessel wall-interface model (1)
- tumorigenesis (1)
- tumormicroenvironment (1)
- tumors (1)
- ubiquitin (1)
- up regulation (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculogenesis (1)
- venetoclax (1)
Institut
- Pathologisches Institut (65)
- Medizinische Klinik und Poliklinik II (20)
- Comprehensive Cancer Center Mainfranken (8)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (7)
- Theodor-Boveri-Institut für Biowissenschaften (7)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (6)
- Urologische Klinik und Poliklinik (5)
- Medizinische Klinik und Poliklinik I (4)
- Kinderklinik und Poliklinik (3)
- Klinik und Poliklinik für Nuklearmedizin (3)
Sonstige beteiligte Institutionen
Diagnosing any of the more than 30 types of T-cell lymphomas is considered a challenging task for many pathologists and currently requires morphological expertise as well as the integration of clinical data, immunophenotype, flow cytometry and clonality analyses. Even considering all available information, some margin of doubt might remain using the current diagnostic procedures. In recent times, the genetic landscape of most T-cell lymphomas has been elucidated, showing a number of diagnostically relevant mutations. In addition, recent data indicate that some of these genetic alterations might bear prognostic and predictive value. Extensive genetic analyses, such as whole exome or large panel sequencing are still expensive and time consuming, therefore limiting their application in routine diagnostic. We therefore devoted our effort to develop a lean approach for genetic analysis of T-cell lymphomas, focusing on maximum efficiency rather than exhaustively covering all possible targets. Here we report the results generated with our small amplicon-based panel that could be used routinely on paraffin-embedded and even decalcified samples, on a single sample basis in parallel with other NGS-panels used in our routine diagnostic lab, in a relatively short time and with limited costs. We tested 128 available samples from two German reference centers as part of our routine work up (among which 116 T-cell lymphomas), which is the largest routine diagnostic series reported to date. Our results showed that this assay had a very high rate of technical success (97%) and could detect mutations in the majority (79%) of tested T-cell lymphoma samples.